Form 8-K - Current report:
SEC Accession No. 0001628280-23-024065
Filing Date
2023-06-30
Accepted
2023-06-30 17:20:45
Documents
12
Period of Report
2023-06-26
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230626.htm   iXBRL 8-K 28323
  Complete submission text file 0001628280-23-024065.txt   157345

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230626.xsd EX-101.SCH 2013
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230626_lab.xml EX-101.LAB 24139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230626_pre.xml EX-101.PRE 12611
6 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230626_htm.xml XML 4280
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 231062776
SIC: 2834 Pharmaceutical Preparations